Drugs / Flebogamma 5% DIF
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT02176863 | Sep 2014 → Nov 2022 | postpoliomyelitis syndrome | Grifols, S.A. | Terminated | Met primary Stop: Business |
| Phase 41 trial | ||||||
| Phase 4 | NCT00634569 | May 2008 → Mar 2011 | immunodeficiency disease | Grifols, S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flebogamma 5% DIF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02176863 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous Immune Globulin (Human)” NCT00634569 ↗ |
| Route | Intravenous | “Intravenous Immune Globulin (Human)” NCT00634569 ↗ |